ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,739.90
0.28%
S&P ASX All Technology
3,077.80
0.36%
Brent Oil
86.695
0.29%
US Dollar vs AUD
1.4912
-0.56%
Bitcoin
60,315.50
-2.76%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. XOMA Corporation (XOMAP)

  7. XOMA Corporation (XOMAP) News

XOMAP

XOMA (XOMAP)

XOMA Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XOMAP
DateTimeSourceHeadlineSymbolCompany
20/06/202421:30GlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAPXOMA Corporation
18/06/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:XOMAPXOMA Corporation
18/06/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:XOMAPXOMA Corporation
14/06/202406:31Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:XOMAPXOMA Corporation
12/06/202421:30GlobeNewswire Inc.XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review VoucherNASDAQ:XOMAPXOMA Corporation
31/05/202406:43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Corporation
18/05/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Corporation
18/05/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Corporation
18/05/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Corporation
18/05/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Corporation
18/05/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Corporation
18/05/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Corporation
16/05/202421:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Corporation
14/05/202421:30GlobeNewswire Inc.XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQNASDAQ:XOMAPXOMA Corporation
09/05/202421:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Corporation
09/05/202421:35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XOMAPXOMA Corporation
09/05/202421:30GlobeNewswire Inc.XOMA Reports First Quarter 2024 Financial Results and Highlights Recent ActivitiesNASDAQ:XOMAPXOMA Corporation
30/04/202421:30GlobeNewswire Inc.XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%NASDAQ:XOMAPXOMA Corporation
25/04/202421:30GlobeNewswire Inc.XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAPXOMA Corporation
04/04/202400:00GlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:XOMAPXOMA Corporation
21/03/202422:30GlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAPXOMA Corporation
20/03/202407:05GlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:XOMAPXOMA Corporation
11/03/202421:56Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:XOMAPXOMA Corporation
09/03/202408:34Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:XOMAPXOMA Corporation
08/03/202423:39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Corporation
08/03/202423:30GlobeNewswire Inc.XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAPXOMA Corporation
05/03/202409:24Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:XOMAPXOMA Corporation
28/02/202423:30GlobeNewswire Inc.XOMA to Present at Upcoming Investor Conferences in MarchNASDAQ:XOMAPXOMA Corporation
17/02/202401:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Corporation
17/02/202400:00GlobeNewswire Inc.XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightNASDAQ:XOMAPXOMA Corporation
 Showing the most relevant articles for your search:NASDAQ:XOMAP

Your Recent History

ASX
CSL
CSL
ASX
CBA
Commonwealth Bank Of Aus...
NASDAQ
GOOGL
Alphabet
ASX
XFL
S&P ASX 50
ASX
XAO
Australian SE All Ordina...
SPI
SP500
S&P 500
ASX
XMM
S&P ASX 300 Metals and M...
NASDAQ
AMZN
Amazon.com
ASX
QBE
QBE Insurance
ASX
WOW
Woolworths
NYSE
XOM
Exxon Mobil
ASX
ANZ
Australia And New Zealan...
ASX
ORG
Origin Energy
NYSE
KO
Coca Cola
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved